11/12
01:24 pm
apvo
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
11/10
08:18 am
apvo
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors [Yahoo! Finance]
Medium
Report
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors [Yahoo! Finance]
11/7
01:12 am
apvo
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
10/8
08:38 am
apvo
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter [Yahoo! Finance]
Low
Report
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter [Yahoo! Finance]
10/3
03:30 pm
apvo
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
9/20
09:50 am
apvo
Aptevo Therapeutics (NASDAQ:APVO) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
Aptevo Therapeutics (NASDAQ:APVO) was upgraded by analysts at Zacks Research to a "hold" rating.
9/18
06:43 am
apvo
Aptevo Therapeutics (NASDAQ:APVO) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
High
Report
Aptevo Therapeutics (NASDAQ:APVO) was upgraded by analysts at Roth Capital to a "strong-buy" rating.